Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
GH Research ( (GHRS) ) has issued an announcement.
On February 4, 2025, GH Research PLC announced the pricing of its public offering in the United States, raising approximately $150 million through the sale of 10 million ordinary shares at $15 each. The offering, managed by Cantor, Stifel, and RBC Capital Markets, aims to enhance the company’s financial capabilities to advance its initiatives in the biopharmaceutical sector.
More about GH Research
GH Research PLC is a clinical-stage biopharmaceutical company focused on developing innovative treatments for depression, specifically targeting treatment-resistant depression with its proprietary mebufotenin therapies.
YTD Price Performance: 106.26%
Average Trading Volume: 288,508
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $936M
See more data about GHRS stock on TipRanks’ Stock Analysis page.